Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720531 | 1.00 | CTSK (0.50) | CTSKBTKGAANFKB1NFKB2 | |
| SCHEMBL8320677 | 1.00 | CTSK (0.50) | CTSKBTKGAANFKB1NFKB2 | |
| SCHEMBL117269 | 0.91 | BTK (0.51) | CTSKBTKGAANFKB1NFKB2 | |
| SCHEMBL21597571 | 0.90 | BTK (0.55) | CTSKBTKGAANFKB1NFKB2 | |
| SCHEMBL10239204 | 0.90 | BTK (0.55) | CTSKBTKGAANFKB1NFKB2 | |
| SCHEMBL132145 | 0.90 | BTK (0.55) | CTSKBTKGAANFKB1NFKB2 | |
| SCHEMBL24874466 | 0.89 | BTK (0.54) | CTSKBTKGAANFKB1NFKB2 | |
| SCHEMBL13735251 | 0.89 | BTK (0.54) | CTSKBTKGAANFKB1NFKB2 | |
| Bicarbonate SCHEMBL3395208 | 0.88 | BTK (0.53) | CTSKBTKGAANFKB1NFKB2 | |
| SCHEMBL570801 | 0.85 | GAA (0.54) | CTSKBTKGAANFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2025-04-10 | — | — | US | disclosed |
| US-12240828-B2 | Heteroaromatic compounds as vanin inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-03-04 | — | — | US | disclosed |
| EP-3890828-B1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2025-02-19 | — | — | EP | disclosed |
| CN-113226462-B | Heteroaromatic compounds as VANIN inhibitors | 勃林格殷格翰国际公司 | 2025-02-11 | — | — | CN | disclosed |
| US-12209102-B2 | Heterocyclic compounds and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2025-01-28 | — | — | US | disclosed |
| EP-4489738-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20240425522-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-12-26 | — | — | US | disclosed |
| US-20240425525-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-12-26 | — | — | US | disclosed |
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-31 | — | — | US | disclosed |
| US-20240360085-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| WO-2009056520-A1 | AZABICYCLO[3.2.1]OCTANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009023269-A2 | 4-(9-(3, 3-DIFLUOROCYCLOPENTYL) -5, 7, 7-TRIMETHYL-6-OXO-6, 7, 8, 9-TETRAHYDRO-5H-PYRIMIDO [4, 5-B[1, 4] DIAZEPIN-2-YLAMINO)-3-METHOXYBENZAMIDE DERIVATIVES AS INHIBITORS OF THE HUMAN PROTEIN KINASES PLK1 TO PLK4 FOR THE TREATMENT OF PROLIFERATIVE DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-19 | — | — | WO | disclosed |
| US-7452893-B2 | 4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists | MERCK & CO., INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20070037829-A1 | e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients | MERCK & CO., INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2005019221-A1 | 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-5925624-A | ANTIINFLAMMATORY AGENTS TREATING PATIENTS WITH INFLAMMATORY CONDITIONS SUSCEPTIBLE TO LEUKOCYTE-INDUCED TISSUE DAMAGE | GLAXO GROUP LIMITED (GB) | 1999-07-20 | — | — | US | disclosed |
| US-5889178-A | N-(2,2-DIPHENYLETHYL)-DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-03-30 | — | — | US | disclosed |
| EP-0680488-B1 | 2,6-DIAMINOPURINE DERIVATIVES | GLAXO GROUP LTD (GB) | 1998-04-08 | — | — | EP | disclosed |
| EP-0680488-A1 | 2,6-DIAMINOPURINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1995-11-08 | — | — | EP | disclosed |
| WO-1994017090-A1 | 2,6-DIAMINOPURINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1994-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425522-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | CTSK 2973/4885BTK 134/4885GAA 3427/4885 |
| US-12240828-B2 | Heteroaromatic compounds as vanin inhibitors | VHL, FANCI, PAH | CTSK 2160/4885BTK 1178/4885GAA 105/4885 |
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | CTSK 1490/4885BTK 3650/4885GAA 771/4885 |
| US-12209102-B2 | Heterocyclic compounds and uses thereof | TP53, HRAS, KRAS | CTSK 2973/4885BTK 134/4885GAA 3427/4885 |
| US-20240425525-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | CTSK 2973/4885BTK 134/4885GAA 3427/4885 |
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CTSK 1471/4885BTK 2881/4885GAA 2658/4885 |
| US-20070037829-A1 | e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients | GRIN2B, GRIN3A, GRIN2A | CTSK 1457/4885BTK 4497/4885GAA 171/4885 |
| US-20240360085-A1 | Glucose Uptake Inhibitors | SLC2A3, SLC2A1, SLC2A4 | CTSK 2655/4885BTK 2858/4885GAA 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.